Evidence map›Paper›PMID 36071851›Full record

ArticleFrontiers in pharmacology2022

Nalidixic acid potentiates the antitumor activity in sorafenib-resistant hepatocellular carcinoma

Zhi-Yong Liu, Dan-Ying Zhang, Xia-Hui Lin, Jia-Lei Sun, Weinire Abuduwaili, Guang-Cong Zhang, Ru-Chen Xu, Fu Wang, Xiang-Nan Yu, Xuan Shi and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Increased PRP19 in Hepatocyte Impedes B Cell Function to Promote Hepatocarcinogenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Zhi-Yong LiuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Dan-Ying ZhangDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Xia-Hui LinDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Jia-Lei SunDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Weinire AbuduwailiDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Guang-Cong ZhangDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Ru-Chen XuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Fu WangDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Xiang-Nan YuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Xuan ShiDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Bin DengDepartment of Gastroenterology, The Affiliated Hospital of Yangzhou University, Yangzhou, China.
Ling DongDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Shu-Qiang WengDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Ji-Min ZhuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Xi-Zhong ShenDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Tao-Tao LiuDepartment of Gastroenterology and Hepatology, Zhongshan Hospital of Fudan University, Shanghai, China.
Fudan University · CNSun Yat-sen University · CNThe First Affiliated Hospital, Sun Yat-sen University · CNZhongshan Hospital · CNShanghai Institute of Hematology · CNYangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sorafenib resistance is often developed and impedes the benefits of clinical therapy in hepatocellular carcinoma (HCC) patients. However, the relationship between sorafenib resistance and tumor immune environment and adjuvant drugs for sorafenib-resistant HCC are not systemically identified. This study first analyzed the expression profiles of sorafenib-resistant HCC cells to explore immune cell infiltration levels and differentially expressed immune-related genes (DEIRGs). The prognostic value of DEIRGs was analyzed using Cox regression and Kaplan-Meier analysis based on The Cancer Genome Atlas. The primary immune cells infiltrated in sorafenib-resistant HCC mice were explored using flow cytometry (FCM). Finally, small-molecule drugs for sorafenib-resistant HCC treatment were screened and validated by experiments. The CIBERSORT algorithm and mice model showed that macrophages and neutrophils are highly infiltrated, while CD8

Indexed as

adjuvant drugsbioinformatics analysisimmune gene signaturesorafenib resistancetumor immune microenvironment

Identifiers

PMID36071851
PMCPMC9441713
OpenAlexW4292554345

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.